Current evidence suggests that only four DPYD and TYMS variants should make up the panel of genetic biomarkers for testing for toxicity to capecitabine monotherapy, according to the results of a recent study.
The use of full-spectrum colonoscopy significantly decreased the number of adenomas missed during an examination compared with the use of forward-viewing colonoscopy, according to the results of an international, multicenter study.
The combination of bortezomib, lenalidomide, and dexamethasone resulted in a partial response or better in more than 60% of patients with relapsed or refractory multiple myeloma, according to results of a phase II trial.
Single patients with soft-tissue sarcoma of the extremities had worse overall survival and were less likely to undergo several important treatment options compared with their married counterparts, according to results of a recent study.
Results of a large meta-analysis indicated that treatment with lenalidomide for newly diagnosed multiple myeloma was associated with an increased risk for developing secondary hematologic malignancies.
The anti-programmed death 1 (PD-1) drug nivolumab may increase overall survival in patients with advanced melanoma with a safe and acceptable long-term safety profile, according to the results of a recent study.